Korean Media: Seven out of Ten Technology Transfer Projects, China's Biotechnology Rises Rapidly!
On December 15, the Korean media "Nikkei" published an article stating that this year, with Chinese biotechnology companies rapidly expanding their influence in the global technology transfer market, there are signs of changes in the technology transaction landscape.
According to a report recently released by Kiwoom Securities Research Center, China's technology transfer volume accounted for 30% of the global total this year, second only to the United States. In major transactions ranked highly, China also holds a significant advantage. This trend indicates that global pharmaceutical companies value China's technical implementation capability and R&D speed, driving the center of technology transactions to shift towards China.
The report shows that seven out of the top ten technology transactions this year involved Chinese enterprises and global pharmaceutical companies. Particularly worth noting is that China not only dominates in the number of technology transfer transactions, but also holds the largest share in milestone collaborations, making it the biggest beneficiary in the technology transfer market.
The share of China in the technology transfer field has also increased to 30%, significantly narrowing the gap with the United States (37%). This indicates that China's position in the biotechnology field is shifting from a simple "emerging economy" to an actual center.
The report emphasized the advantages of Chinese enterprises in clinical trial speed, clear strategic positioning, and global cooperation experience. The report also found that enterprises that have reached a large number of transactions demonstrate particularly strong "execution capability," which is a key factor in driving the growth of transaction value. In addition, the report pointed out that the return rate of Chinese biotechnology companies this year has reached as high as 62%, ranking first globally, indicating that the market's confidence in China's technological strength is growing.
China's technological competitiveness also stands out. According to the report, this year's technology demand is concentrated in the fields of dual-antibody, siRNA, and AI drug development. Top technology transfer transactions are also concentrated in these areas, including several Chinese companies such as Hengrui and Sansheng Pharmaceutical.
The report concludes that the technology transfer market in 2025 is not a temporary change, but a structural transformation. Although the United States still holds the largest share in the technology transfer market, China's rapid rise in large-scale transactions highlights the potential shift in market leadership.
Notably, the most important milestone transactions this year revolved around Chinese companies, which is interpreted as an important sign of the structural shift of the technology transfer center from the United States to China.
The technical export performance of Chinese biotechnology companies is mainly concentrated in a few large transactions. The report analyzes that Chinese enterprises are gradually meeting the needs of global pharmaceutical companies in terms of clinical trial speed and product portfolio management.
Therefore, some views suggest that global technology demand may continue to focus on specific therapies and Chinese platforms. At the same time, it is predicted that this shift may affect future global technology transfer strategies and the collaboration structure between pharmaceutical companies.
Original: toutiao.com/article/1851540017895564/
Statement: This article represents the views of the author.